Navigation Links
FDA Approves Tradjenta™ (linagliptin) Tablets for the Treatment of Type 2 Diabetes
Date:5/2/2011

ith TRADJENTA, physicians will have another option for managing type 2 diabetes, a potentially devastating condition."

TRADJENTA 5 mg once daily was approved based on a clinical trial program which included approximately 4,000 adults with type 2 diabetes. Included in the program were placebo-controlled studies evaluating TRADJENTA as monotherapy and in combination with the commonly prescribed medications for type 2 diabetes –  metformin, sulfonylurea or pioglitazone. TRADJENTA showed statistically significant A1C reductions of up to 0.7 percent when used as monotherapy (compared to placebo). When used in combination with metformin, sulfonylurea, and metformin plus sulfonylurea, the addition of TRADJENTA resulted in significant A1C reductions of 0.6, 0.5, and 0.6 percent respectively (compared to placebo). In the initial combination of TRADJENTA plus pioglitazone, significant reductions in A1C of 0.5 percent were observed compared to placebo.  

Treatment with TRADJENTA also produced significant reductions in fasting plasma glucose (FPG) compared to placebo, when used as monotherapy and in combination with metformin, sulfonylurea or pioglitazone. Treatment with TRADJENTA produced significant reductions in two-hour post-prandial glucose (PPG) levels compared with placebo as monotherapy and when used in combination with metformin. FPG is used to determine glucose levels in a fasting state (usually upon wakening in the morning), and PPG is used to determine glucose levels after meals (usually two hours after eating).

In controlled studies, change from baseline in body weight did not differ significantly between groups when TRADJENTA was administered as monotherapy, in combination with metformin or in combination with metformin plus sulfonylurea. Patients treated with TRADJENTA exhibited a significant mean decrease from baseline body weight compared to a significant weight gain in patients administered sulfonylurea (-1.1 kg vs. +1.4 kg
'/>"/>

SOURCE Boehringer Ingelheim Pharmaceuticals, Inc.; Eli Lilly and Company
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. FDA Approves Lillys Osteoporosis Drug EVISTA(R) (raloxifene HCl) to Reduce The Risk of Invasive Breast Cancer in Two Populations of Postmenopausal Women
2. Health Canada Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for HIV
3. FDA Approves Cymbalta(R) for Maintenance Treatment of Major Depressive Disorder
4. European Commission Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for Virologically Suppressed Adults With HIV-1 Infection
5. FDA Approves MiddleBrooks Amoxicillin PULSYS for Pharyngitis/Tonsillitis in Adolescents and Adults
6. FDA Approves XYZAL(R) (levocetirizine dihydrochloride) Oral Solution for the Relief of Seasonal and Year Round Allergies and Chronic Idiopathic Urticaria
7. UM Maryland Industrial Partnerships Program Approves 18 Collaborative Research Projects, Worth $4.4 Million, Between University Faculty, State Technology Companies
8. U.S. Food and Drug Administration Approves ABILIFY(R) (aripiprazole) for the Acute Treatment of Manic and Mixed Episodes Associated With Bipolar I Disorder in Pediatric Patients (10 to 17 Years of Age)
9. U.S. Food and Drug Administration Approves ORENCIA(R) (abatacept) for the Treatment of Moderate-to-Severe Polyarticular Juvenile Idiopathic Arthritis (JIA) in Patients Six Years and Older
10. FDA Approves HIFU Clinical Trial for Recurrent Prostate Cancer
11. EPA Approves XDS-CALUX(R) as Alternate Dioxin Test Method 4435
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... 18, 2014 Somewhere between dropping five pounds ... forgotten. But Audicus , a next-generation hearing aids ... new year. Hearing loss is the third ... though it is often unaddressed. Forty-eight million Americans have ... hearing aid, mainly due to price. Hearing aids traditionally ...
(Date:12/19/2014)... , Dec. 18, 2014  Sage Analytics ... generation of equipment for the testing of marijuana ... of the new Luminary™ Profiler, the industry,s first ... measurement in a cost-effective, portable unit. ... specific needs of the cannabis industry, the Luminary™ ...
(Date:12/19/2014)... Capnia, Inc. (NASDAQ: CAPN ... based on its proprietary Sensalyze™ Technology Platform for ... results for the third quarter and nine months ... completion of our initial public offering (IPO), we ... initiated CoSense® commercial launch," said Anish Bhatnagar, M.D., ...
Breaking Medicine Technology:Audicus Will Help People Resolve to Hear Better in 2015 2Sage Analytics Develops Breakthrough System for Potency Testing of Cannabis Products 2Capnia Reports Third Quarter 2014 Financial Results 2Capnia Reports Third Quarter 2014 Financial Results 3Capnia Reports Third Quarter 2014 Financial Results 4Capnia Reports Third Quarter 2014 Financial Results 5Capnia Reports Third Quarter 2014 Financial Results 6Capnia Reports Third Quarter 2014 Financial Results 7Capnia Reports Third Quarter 2014 Financial Results 8
... - Appoints Director, Clinical Operations and Manager, Medical ... Cellectar LLC, (Cellectar), a,privately-held radiopharmaceuticals company that designs ... cancers, today announced the,appointment of Ernest Allen as ... Medical Affairs. These appointments reflect the,advancement of the ...
... Calif., Oct. 3 Anthera Pharmaceuticals,Inc., a privately-held ... inflammatory diseases,announced today the completion of enrollment and ... its lead compound, A-002 for stable coronary,artery disease. ... the end of,the year. "We are pleased ...
Cached Medicine Technology:Cellectar Expands Clinical Management Team 2Anthera Announces Completion of Enrollment and Dosing in Phase II Trial of A-002 for the Treatment of Cardiovascular Disease 2Anthera Announces Completion of Enrollment and Dosing in Phase II Trial of A-002 for the Treatment of Cardiovascular Disease 3
(Date:12/19/2014)... 2014 Slone Partners , ... medicine, healthcare information technology, and laboratory testing industries, ... Chief Operating Officer. The announcement comes after a ... a strengthened presence in Boston and several new ... and breathes the client experience," said Adam Slone, ...
(Date:12/19/2014)... 19, 2014 This is a professional ... global Gliquidone industry with a focus on the Chinese ... status of the Gliquidone manufacturers and is a valuable ... interested in the industry. , Firstly, the report provides ... applications and manufacturing technology. Then, the report explores the ...
(Date:12/19/2014)... (PRWEB) December 19, 2014 The ... ski club in Southern Vermont’s Deerfield Valley, announced today ... inspired by classic rock songs. , Three time ... with a private concert followed by a trail naming ... new trail names include: “I’m Alright” the theme song ...
(Date:12/19/2014)... new study suggests a possible link between certain menopause ... sweats -- and higher rates of hip fractures and ... affecting about 60 percent of women. The hormonal changes ... then face a higher risk of weakened bones and ... or severe menopausal symptoms are more likely to have ...
(Date:12/19/2014)... Amy Norton HealthDay ... Children born to moms who were exposed to high levels ... risk of developing autism, a U.S. study suggests. Researchers ... between 1990 and 2002, those exposed to the most air ... baby who later developed autism. And exposure during the third ...
Breaking Medicine News(10 mins):Health News:Slone Partners Promotes Leslie Loveless to Chief Operating Officer 2Health News:Gliquidone Industry Global and China Analysis for 2019, Now Available at ReportsnReports.com 2Health News:Gliquidone Industry Global and China Analysis for 2019, Now Available at ReportsnReports.com 3Health News:Gliquidone Industry Global and China Analysis for 2019, Now Available at ReportsnReports.com 4Health News:Gliquidone Industry Global and China Analysis for 2019, Now Available at ReportsnReports.com 5Health News:Gliquidone Industry Global and China Analysis for 2019, Now Available at ReportsnReports.com 6Health News:The Hermitage Club Officially Names Four Ski Trails after Iconic Rock Songs by Grammy Award Winner Kenny Loggins 2Health News:Severe Hot Flashes During Menopause May Raise Hip Fracture Risk Later: Study 2Health News:Smog Exposure During Pregnancy Linked to Autism Risk 2Health News:Smog Exposure During Pregnancy Linked to Autism Risk 3
... ALLEGAN, Mich., Jan. 28 Perrigo Company (Nasdaq: ... its Board of Directors declared a quarterly dividend ... 2009 to shareholders of record on February 27, ... healthcare supplier that develops, manufactures and distributes over-the-counter ...
... has been linked to cancer, diabetes, heart disease, developmental ... A, a controversial chemical used to harden plastics for ... appears to remain in the body much longer than ... that exposure to BPA may come from many different ...
... 28 PEAK Surgical, Inc., a medical,device company ... based on a,proprietary technology, announced today that it ... Surgery System for use in general surgery. The ... PEAK PlasmaBlade(TM),family of disposable, low-temperature surgical cutting and ...
... Venture Industry to Step Up Investments in Healthcare Services ... is on the verge of building a "new healthcare ... venture capital firm Psilos Group. But the same report ... Obama administration, the economics of healthcare will not truly ...
... Corporation, a leader in innovative fatigue management solutions for ... has chosen REM Medical as its provider of comprehensive ... obstructive sleep apnea (OSA) diagnostic and treatment services for ... of this serious sleep disorder. The Federal Motor ...
... Snoring Events, Increase in Sleep Quality For Bed ... of Brez premium nasal breathing aids, the first ... proven to reduce snoring and increase overall sleep ... in all Rite Aid and numerous independent pharmacies ...
Cached Medicine News:Health News:Controversial Chemical Lingers Longer in the Body: Study 2Health News:Controversial Chemical Lingers Longer in the Body: Study 3Health News:PEAK Surgical Receives European CE Mark for PEAK(R) Surgery System for Use in General Surgery 2Health News:PEAK Surgical Receives European CE Mark for PEAK(R) Surgery System for Use in General Surgery 3Health News:Obama Reforms Could Spark 'New Healthcare Economy' If Investors Increase Funding, Says Leading Healthcare Venture Firm 2Health News:Obama Reforms Could Spark 'New Healthcare Economy' If Investors Increase Funding, Says Leading Healthcare Venture Firm 3Health News:Obama Reforms Could Spark 'New Healthcare Economy' If Investors Increase Funding, Says Leading Healthcare Venture Firm 4Health News:Gordon Trucking Begins Sleep Apnea Wellness Program with REM Medical Corporation 2Health News:Brez(R), the First Over-the-Counter, Intranasal Breathing Aid Clinically Proven to Reduce Primary Snoring, Debuts in Rite Aid Pharmacies 2Health News:Brez(R), the First Over-the-Counter, Intranasal Breathing Aid Clinically Proven to Reduce Primary Snoring, Debuts in Rite Aid Pharmacies 3Health News:Brez(R), the First Over-the-Counter, Intranasal Breathing Aid Clinically Proven to Reduce Primary Snoring, Debuts in Rite Aid Pharmacies 4
... a multifunctional hybrid configuration, consisting of ... a SOMATOM CT Scanner with Sliding ... to radiation treatment delivery, providing accurate, ... treatment room. The Siemens PRIMATOM System ...
... SOMATOM Sensation is the highly respected ... coronary branches to visualizing plaque. With its ... industrys fastest rotation time of 0.33s, virtually ... z-Sharp Technology, the system delivers unprecedented diagnostic ...
... (DGH 55) is the ultimate in portable pachymeters. ... in weight. The Pachmate is a handheld pachymeter ... The Pachmate will easily fit in a lab ... rugged in design and one of the worlds ...
... integrated system that will perform venous occlusion ... You no longer need to manually control ... with and without reactive hyperemia are included. ... for measurements and the frequency with which ...
Medicine Products: